AR006515A1 - Proceso para la preparacion de (s) -4- { [3- [2 (dimetilamino) etil] -1h- indol-5- il] metil} -2-oxazolidinona; intermediarios de uso exclusivo en dicho proceso; procesos para preparar dichos intermediarios y su uso. - Google Patents

Proceso para la preparacion de (s) -4- { [3- [2 (dimetilamino) etil] -1h- indol-5- il] metil} -2-oxazolidinona; intermediarios de uso exclusivo en dicho proceso; procesos para preparar dichos intermediarios y su uso.

Info

Publication number
AR006515A1
AR006515A1 ARP960103909A AR10390996A AR006515A1 AR 006515 A1 AR006515 A1 AR 006515A1 AR P960103909 A ARP960103909 A AR P960103909A AR 10390996 A AR10390996 A AR 10390996A AR 006515 A1 AR006515 A1 AR 006515A1
Authority
AR
Argentina
Prior art keywords
formula
compound
intermediaries
methyl
indol
Prior art date
Application number
ARP960103909A
Other languages
English (en)
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Publication of AR006515A1 publication Critical patent/AR006515A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Indole Compounds (AREA)

Abstract

Se provee un proceso mejorado para la preparación de (S)-4-{[3-[2-( dimetilamina)etil]-1H-indol-5-il]metil}-2-oxazolidinona donde el procesocomprende: a)formar un carbamato de fórmula (III) a partir de metil 4-nitro- (L)-fenilalaninatohid rocloruro; b)reducir el compuesto de fórmula (III) parabrindar el compuesto de fórmula (IV); c) reducir el grupo metil éster en el compuesto de fórmula (IV) para brindar el compuesto de fórmula (V); d) cerrarel anillo del compuesto defórmula (V) para brindar el compuesto de fórmula (VI); e) formar una sal de diazonio a partir del compuesto de fórmula (VI)seguido por la reducción para brindar el compuesto de fórmula (VII); f) efectuar la reacción de Fishcer delcompuesto de fórmu la (VII) para brindar (S)-4-{[3-[2-(dimetilamina)etil]-1H-indol-5-il]metil}-2-oxazodilinona.
ARP960103909A 1995-08-07 1996-08-07 Proceso para la preparacion de (s) -4- { [3- [2 (dimetilamino) etil] -1h- indol-5- il] metil} -2-oxazolidinona; intermediarios de uso exclusivo en dicho proceso; procesos para preparar dichos intermediarios y su uso. AR006515A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9516145.1A GB9516145D0 (en) 1995-08-07 1995-08-07 Improved chemical synthesis

Publications (1)

Publication Number Publication Date
AR006515A1 true AR006515A1 (es) 1999-09-08

Family

ID=10778867

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP960103909A AR006515A1 (es) 1995-08-07 1996-08-07 Proceso para la preparacion de (s) -4- { [3- [2 (dimetilamino) etil] -1h- indol-5- il] metil} -2-oxazolidinona; intermediarios de uso exclusivo en dicho proceso; procesos para preparar dichos intermediarios y su uso.
ARP030101543A AR046236A2 (es) 1995-08-07 2003-05-02 Proceso para la purificacion de (s)-4-{[3-[2(dimetilamino)etil]-1h-indol-5-il]metil}-2-oxazolidinona y compuesto que se obtiene

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP030101543A AR046236A2 (es) 1995-08-07 2003-05-02 Proceso para la purificacion de (s)-4-{[3-[2(dimetilamino)etil]-1h-indol-5-il]metil}-2-oxazolidinona y compuesto que se obtiene

Country Status (34)

Country Link
US (2) US6084103A (es)
EP (2) EP1227095B1 (es)
JP (6) JP3729503B2 (es)
KR (1) KR100670704B1 (es)
CN (3) CN1244579C (es)
AR (2) AR006515A1 (es)
AT (2) ATE227723T1 (es)
AU (1) AU718413B2 (es)
BR (1) BR9609830A (es)
CA (2) CA2227039C (es)
CZ (2) CZ301603B6 (es)
DE (2) DE69624825T2 (es)
DK (2) DK1227095T3 (es)
ES (2) ES2185790T3 (es)
GB (1) GB9516145D0 (es)
HK (2) HK1047094B (es)
HU (1) HU229966B1 (es)
IL (4) IL156733A (es)
IN (2) IN185148B (es)
MX (1) MX9801044A (es)
MY (1) MY117571A (es)
NO (2) NO311690B1 (es)
NZ (1) NZ315040A (es)
PL (1) PL188805B1 (es)
PT (2) PT843672E (es)
RO (2) RO121816B1 (es)
RU (1) RU2167875C2 (es)
SI (2) SI0843672T1 (es)
SK (1) SK285052B6 (es)
TR (1) TR199800182T1 (es)
TW (1) TW358811B (es)
UA (1) UA53625C2 (es)
WO (1) WO1997006162A1 (es)
ZA (1) ZA966711B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001004088A1 (fr) * 1999-07-09 2001-01-18 Chugai Seiyaku Kabushiki Kaisha Procede de preparation de derives d'amiline
ES2204302B2 (es) 2002-08-07 2005-03-01 Laboratorios Vita, S.A. Procedimiento para la obtencion de un compuesto farmaceuticamente activo.
WO2005075467A2 (en) * 2004-02-06 2005-08-18 Ciba Specialty Chemicals Holding Inc. Crystalline forms of zolmitriptan
EP1812428A2 (en) * 2004-11-19 2007-08-01 Teva Pharmaceutical Industries Ltd Zolmitriptan crystal forms
CN101248184B (zh) 2005-08-25 2013-01-16 宇部兴产株式会社 光学活性（S或R）-α-氨基酸及光学活性（S或R）-α-氨基酸酯的制造方法
EP1981860B1 (en) 2006-01-19 2011-05-25 Matrix Laboratories Ltd Conversion of aromatic diazonium salt to aryl hydrazine
WO2008007390A2 (en) * 2006-07-10 2008-01-17 Natco Pharma Limited An improved process for purification of zolmitriptan
WO2008018090A2 (en) * 2006-08-09 2008-02-14 Matrix Laboratories Ltd An improved process for the preparation of zolmitriptan
CZ2007158A3 (cs) * 2007-02-26 2008-10-22 Zentiva, A. S. Zpusob prípravy zolmitriptanu
CZ301538B6 (cs) * 2007-02-26 2010-04-07 Zentiva, A. S. Zpusob prípravy zolmitriptanu
CN101883766A (zh) * 2007-10-03 2010-11-10 基因里克斯(英国)有限公司 制备佐米曲普坦、其盐和溶剂化物的方法
CN101230047B (zh) * 2008-02-04 2010-08-04 江苏中威药业有限公司 一种4-取代手性噁唑烷酮类化合物的制备方法
US8906949B2 (en) 2010-05-21 2014-12-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Orally disintegrating tablets of zolmitriptan and process for preparing the same
CN101948443B (zh) * 2010-08-17 2012-08-22 河南师范大学 一种简单、高效合成4-取代噁唑烷酮衍生物的方法
EP2691396B1 (en) 2011-03-30 2016-08-10 Brown University Enopeptins, uses thereof, and methods of synthesis thereto
US9006453B2 (en) 2011-09-02 2015-04-14 Emcure Pharmaceuticals Limited Process for preparation of zolmitriptan
CN102964270B (zh) * 2012-11-21 2015-01-07 合肥星宇化学有限责任公司 一种亚硫酸钠还原重氮盐合成肼的方法
CN103275075B (zh) * 2013-06-24 2015-01-07 成都天台山制药有限公司 佐米曲普坦及其制备方法
WO2016037072A2 (en) * 2014-09-04 2016-03-10 Brown University Enopeptin analogas and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8724912D0 (en) * 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
YU48855B (sh) * 1990-06-07 2002-06-19 The Wellcome Foundation Limited Heterociklična jedinjenja i njihovi derivati koji su modifikatori dejstva 5-hidroksi-triptamina i postupak njihovog dobijanja
GB9401436D0 (en) * 1994-01-26 1994-03-23 Wellcome Found Therapeutic heterocyclic compounds
GB9423682D0 (en) * 1994-11-23 1995-01-11 Merck Sharp & Dohme Therapeutic agents
CA2207201A1 (en) * 1994-12-06 1996-06-13 Caroline Henry Azetidine, pyrrolidine and piperidine derivatives as 5ht1 receptor agonists

Also Published As

Publication number Publication date
PL188805B1 (pl) 2005-04-29
PT1227095E (pt) 2006-08-31
EP0843672A1 (en) 1998-05-27
IN189756B (es) 2003-04-19
IN185148B (es) 2000-11-25
HU229966B1 (hu) 2015-03-30
ATE227723T1 (de) 2002-11-15
CN1201460A (zh) 1998-12-09
AU718413B2 (en) 2000-04-13
SK285052B6 (sk) 2006-05-04
ES2185790T3 (es) 2003-05-01
BR9609830A (pt) 1999-03-09
AR046236A2 (es) 2005-11-30
ZA966711B (en) 1997-02-18
CN1317480A (zh) 2001-10-17
IL123171A (en) 2003-10-31
ATE325121T1 (de) 2006-06-15
HK1047094B (zh) 2006-10-13
TW358811B (en) 1999-05-21
TR199800182T1 (xx) 1998-05-21
ES2261545T3 (es) 2006-11-16
JP3739678B2 (ja) 2006-01-25
JP3729503B2 (ja) 2005-12-21
US6084103A (en) 2000-07-04
IL123171A0 (en) 1998-09-24
CZ301603B6 (cs) 2010-04-28
EP1227095A2 (en) 2002-07-31
RO121816B1 (ro) 2008-05-30
AU6663496A (en) 1997-03-05
HUP9900188A2 (hu) 1999-05-28
CN1244579C (zh) 2006-03-08
WO1997006162A1 (en) 1997-02-20
DE69636107T2 (de) 2007-05-03
CN1142904C (zh) 2004-03-24
NO20005187D0 (no) 2000-10-16
CA2572508C (en) 2010-03-30
MX9801044A (es) 1998-05-31
NO980522D0 (no) 1998-02-06
DE69636107D1 (de) 2006-06-08
CZ293050B6 (cs) 2004-01-14
RU2167875C2 (ru) 2001-05-27
RO119618B1 (ro) 2005-01-28
CA2227039C (en) 2007-12-04
JP2002097178A (ja) 2002-04-02
CA2227039A1 (en) 1997-02-20
NZ315040A (en) 2000-01-28
KR19990036165A (ko) 1999-05-25
HK1047094A1 (en) 2003-02-07
DE69624825T2 (de) 2003-09-04
SI0843672T1 (en) 2003-04-30
SK15498A3 (en) 1998-06-03
IL156733A0 (en) 2004-02-08
US6160123A (en) 2000-12-12
MY117571A (en) 2004-07-31
UA53625C2 (uk) 2003-02-17
EP1227095B1 (en) 2006-05-03
JP2006077025A (ja) 2006-03-23
EP1227095A3 (en) 2003-11-19
PL324881A1 (en) 1998-06-22
CN1403455A (zh) 2003-03-19
JP2002308858A (ja) 2002-10-23
JPH11513023A (ja) 1999-11-09
JP4634286B2 (ja) 2011-02-16
HK1009129A1 (en) 1999-05-28
IL148030A0 (en) 2002-09-12
CZ35298A3 (cs) 1998-06-17
CN1092657C (zh) 2002-10-16
CA2572508A1 (en) 1997-02-20
KR100670704B1 (ko) 2007-07-11
IL148030A (en) 2010-05-17
DK0843672T3 (da) 2003-02-17
HUP9900188A3 (en) 1999-11-29
GB9516145D0 (en) 1995-10-04
NO20005187L (no) 1998-02-06
JP2002037786A (ja) 2002-02-06
DK1227095T3 (da) 2006-07-31
DE69624825D1 (de) 2002-12-19
NO311691B1 (no) 2002-01-07
NO980522L (no) 1998-02-06
SI1227095T1 (sl) 2006-08-31
JP2006225406A (ja) 2006-08-31
EP0843672B1 (en) 2002-11-13
IL156733A (en) 2007-07-04
NO311690B1 (no) 2002-01-07
PT843672E (pt) 2003-03-31

Similar Documents

Publication Publication Date Title
AR006515A1 (es) Proceso para la preparacion de (s) -4- { [3- [2 (dimetilamino) etil] -1h- indol-5- il] metil} -2-oxazolidinona; intermediarios de uso exclusivo en dicho proceso; procesos para preparar dichos intermediarios y su uso.
OA09523A (fr) Nouveaux dérivés de l'érythromycine leur procédé de préparation les nouveaux intermediaires obtenus et leur application comme médicaments
AU2003217274A1 (en) Peroxisome proliferator activated receptor modulators
DE69007603T2 (de) Phenyläthanolaminomethyltetraline, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel.
DK0411734T3 (da) Antigestagene 11beta-aryl-16alfa,17alfa-cyklohexano-østra-4,9-diener
KR950701905A (ko) 치환된 (아릴알킬아미노벤질)아미노프로피온아미드 유도체, 이의 제조방법 및 간질치료제, 신경보호제 및 우울증치료제로서의 이의 용도(Substituted (arylalkyla-minobenzyl)aminopropionamide derivatives, their preparation and use anti-epileptic, neuroprotective and antidepressant agents)
KR930017886A (ko) 알도오스 환원효소 저해물질
NO982107D0 (no) Fremstilling av et salt av klavulansyre
CA2164152A1 (en) New compounds of the secomacrolide and secoazalide class and a process for the preparation thereof
JPS5492956A (en) 2-oxobenzothiazoline fatty acid amide and its preparation
IT1270834B (it) Disolfuro chinolico
JPS5569552A (en) Optically active alpha-acylamino-gamma-cyanobutyric acid ester
ES2175092T3 (es) Preparacion de compuestos hidroxilados mediante bioconversion de dioxigenasa.
ATE194388T1 (de) Stereoselektive herstellung von 2-substituierten succinatderivaten
JPS5437886A (en) Preparation of l-threonine by fermentation
ES8203331A1 (es) Un procedimiento para la preparacion de derivados de tirosi-na.
EP0382418A3 (en) Process for optically active 3-thiolanyl sulfonate esters
JPS5283361A (en) Synthesis of (e)-2-(5-(beta-substituted vinyl)-2-thienyl) fatty acids and their esters
JPS5569548A (en) Optically active alpha-acylamino-gamma-formylbutyric acid ester
DE58906759D1 (de) Substituierte thienylethylamine und Verfahren zu deren Herstellung.
JPS56123973A (en) Novel tetrazol-5-ylthiol ester and its preparation
JPS55344A (en) 2-nitrosoiminobenzthiazoline derivative
KR970042522A (ko) N-치환 헤테로 화합물, 이의 제조방법 및 이를 함유한 약제학적 조성물
JPS5661364A (en) Dihydroxyphthalazinone derivative and its preparation

Legal Events

Date Code Title Description
FG Grant, registration